Pharmacotherapy for post-traumatic stress disorder

References

• Diagnostic and Statistical Manual of Mental Disorders (4th Edition) (DSM-IV). American Psychiatric Association, DC, USA 424–429 (1994).
   Google Scholar
• Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry52, 1048–1060 (1995).
   PubMed Web of Science ®Google Scholar
• Yehuda R. Post-traumatic stress disorder. N. Engl. J. Med.346, 106–114 (2002).
   Google Scholar
• Foa EB, Davidson JR, Frances A. Treatment of posttraumatic stress disorder. J. Clin. Psychiatry60(Suppl. 16), 6–74 (1999).
   Google Scholar
• van der Kolk BA. The psychobiology of posttraumatic stress disorder. J. Clin. Psychiatry58, 16–24 (1997).
   PubMed Web of Science ®Google Scholar
• Pitman RK, Gilbertson MW, Gurvits TV et al. Clarifying the origin of biological abnormalities in PTSD through the study of identical twins discordant for combat exposure. Ann. NY Acad. Sci.1071, 242–254 (2006).
   PubMed Web of Science ®Google Scholar
• Australian Centre for Posttraumatic Mental Health. Australian Guidelines for the Treatment of Adults with Acute Stress Disorder and Posttraumatic Stress Disorder. ACPMH, Melbourne, Australia (2007).
   Google Scholar
• Post-traumatic stress disorder (PTSD). The Management of PTSD in Adults and Children in Primary and Secondary Care. National Institute for Clinical Excellence, London, UK (2005).
   Google Scholar
• Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. American Psychiatric Association, DC, USA (2004).
   Google Scholar
• Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int. J. Neuropsychopharmacol.8, 293–302 (2005).
   PubMed Web of Science ®Google Scholar
• Cahill SP, Foa EB, Rothbaum BO et al. Augmentation of sertraline with prolonged exposure (PE) in the treatment of PTSD: does PE protect against relapse? Presented at: The Annual Convention of the Anxiety Disorders Association of America. Toronto, ON, Canada 27–30 March, 2003 (Poster).
   Google Scholar
• Boscarino JA. Diseases among men 20 years after exposure to severe stress: implications for clinical research and medical care. Psychosom. Med.59, 605–614 (1997).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Davidson JRT. Trauma: prevalence, impairment, service use, and cost. J. Clin. Psychiatry58(Suppl. 9), 5–11 (1997).
   PubMed Web of Science ®Google Scholar
• Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP24, 1093–1097 (1990).
   PubMedGoogle Scholar
• Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry153, 311–320 (1996).
   PubMed Web of Science ®Google Scholar
• Hogben GL, Cornfield RB. Treatment of traumatic war neurosis with phenelzine. Arch. Gen. Psychiatry38, 440–445 (1981).
   PubMed Web of Science ®Google Scholar
• Levenson H, Lanman R, Rankin M. Traumatic ward neurosis and phenelzine. Arch. Gen. Psychiatry39, 1345 (1982).
   Google Scholar
• Davidson J, Walker JI, Kilts C. A pilot study of phenelzine in the treatment of post-traumatic stress disorder. Br. J. Psychiatry150, 252–255 (1987).
   Google Scholar
• Lere B, Bleich A, Kotler M, Garb R, Hertzberg M, Levin B. Posttraumatic stress disorder in Israeli combat veterans. Effect of phenelzine treatment. Arch. Gen. Psychiatry44, 976–981 (1987).
   Google Scholar
• Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J. Nerv. Ment. Dis.179, 366–370 (1991).
   PubMed Web of Science ®Google Scholar
• Falcon S, Ryan C, Chamberlain K, Curtis G. Tricyclics: possible treatment for posttraumatic stress disorder. J. Clin. Psychiatry46, 385–388 (1985).
   Web of Science ®Google Scholar
• Reist C, Kauffmann CD, Haier RJ, Sangdahl C, DeMet EM, Chicz-DeMet A et al. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am. J. Psychiatry146, 513–516 (1989).
   PubMed Web of Science ®Google Scholar
• Davidson J, Kudler H, Smith R et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch. Gen. Psychiatry47, 259–266 (1990).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Kudler HS, Saunders WB et al. Predicting response to amitriptyline in posttraumatic stress disorder. Am. J. Psychiatry150, 1024–1029 (1993).
   PubMed Web of Science ®Google Scholar
• Blake DJ. Treatment of posttraumatic stress disorder with tricyclic antidepressants. South Med. J.79, 201–204 (1986).
   Web of Science ®Google Scholar
• den Boer M, Op der Belde W, Falger RJ, Hoveas JE, deFroen JH, van Duijn H. Fluvoxamine treatment for chronic PTSD. Psychother. Psychosomat.57, 158–163 (1991).
   Google Scholar
• McDougle CJ, Southwick SM, Charney DS, James St RL. An open trial of fluoxetine in the treatment of posttraumatic stress disorder. J. Clin. Psychopharmacol.11, 325–327 (1991).
   PubMed Web of Science ®Google Scholar
• Shay J. Fluoxetine reduces explosiveness and elevates mood of Vietnam combat veterans with PTSD. J. Trauma Stress5, 97–101 (1992).
   Web of Science ®Google Scholar
• Nagy LM, Morgan CA, Southwick SM, Charney DS. Open prospective trial of fluoxetine for posttraumatic stress disorder. J. Clin. Psychopharmacol.13, 107–113 (1993).
   PubMed Web of Science ®Google Scholar
• March JS. Fluoxetine and fluvoxamine in PTSD. Am. J. Psychiatry149, 413 (1992).
   PubMedGoogle Scholar
• van der Kolk BA, Dreyfuss D, Michaels M et al. Fluoxetine in posttraumatic stress disorder. J. Clin. Psychiatry55, 517–522 (1994).
   PubMed Web of Science ®Google Scholar
• Kline NA, Dow BM, Brown SA, Matloff JL. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder. Am. J. Psychiatry151, 621 (1994).
   PubMed Web of Science ®Google Scholar
• Fichtner CG, Arora RC, O’Connor FL, Crayton JW. Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response. Life Sciences54, PL39–PL44 (1994).
   PubMedGoogle Scholar
• Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Syst. Rev. (1), CD002795 (2006).
   Google Scholar
• Davidson JR. Pharmacological treatment of acute and chronic stress following trauma. J. Clin. Psychiatry67(Suppl. 2), 34–39 (2006).
   PubMed Web of Science ®Google Scholar
• Rothbaum BO, Ninan PT, Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J. Trauma Stress9, 865–871 (1996).
   PubMed Web of Science ®Google Scholar
• Brady K, Pearlstein T, Asnis GM et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA283, 1837–1844 (2000).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicentre, double blind comparison of sertraline and placebo in the treatment of post-traumatic stress disorder. Arch. Gen. Psychiatry58, 485–492 (2001).
   PubMed Web of Science ®Google Scholar
• Brady K, Sonne S, Anton RF, Randall CI, Back SE, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin. Exp. Res.29, 395–401 (2005).
   PubMed Web of Science ®Google Scholar
• Zohar J, Amital D, Miodownik C et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J. Clin. Psychopharmacol.22, 190–195 (2002).
   PubMed Web of Science ®Google Scholar
• Stein DJ, van der Kolk BA, Austin C, Fayyad R, Clary C. Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuse. Ann. Clin. Psychiatry18, 243–249 (2006).
   PubMedGoogle Scholar
• Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br. J. Psychiatry175, 17–22 (1999).
   PubMed Web of Science ®Google Scholar
• Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br. J. Psychiatry181, 315–320 (2002).
   PubMed Web of Science ®Google Scholar
• Martenyi F, Soldatenkova V. Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: analysis of the veteran group of a placebo-controlled, randomized clinical trial. Eur. Neuropsychopharmacol.16, 340–349 (2006).
   Web of Science ®Google Scholar
• Marmar CR, Schoenfeld F, Weiss DS et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J. Clin. Psychiatry57(Suppl. 8) 66–70 (1996).
   PubMed Web of Science ®Google Scholar
• Marshall RD, Schneier FR, Fallon BA et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J. Clin. Psychopharmacol.18, 10–18 (1998).
   PubMed Web of Science ®Google Scholar
• Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry62, 860–868 (2001).
   PubMed Web of Science ®Google Scholar
• Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry158, 1982–1988 (2001).
   PubMed Web of Science ®Google Scholar
• Marshall RD, Lewis-Fernandez R, Blanco C et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress. Anxiety24, 77–84 (2007).
   PubMed Web of Science ®Google Scholar
• Seedat S, Stein DJ, Emsley RA. Open trial of citalopram in adults with post-traumatic stress disorder. Int. J. Neuropsychpharmacol.3, 135–140 (2000).
   PubMedGoogle Scholar
• Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J. Clin. Psychiatry2067, 1522–1526 (2006).
   Google Scholar
• Tucker P, Ruwe WD, Masters B et al. Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. Biol. Psychiatry56, 121–128 (2004).
   PubMed Web of Science ®Google Scholar
• Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR. Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann. Clin. Psychiatry12, 101–105 (2000).
   PubMedGoogle Scholar
• Martenyi F, Brown EB, Caldwell CD. Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J. Clin. Psychopharmacol.27, 166–170 (2007).
   PubMed Web of Science ®Google Scholar
• Davidson J, Baldwin D, Stein DJ et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch. Gen. Psychiatry63, 1158–1165 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J. Clin. Psychopharmacol.26, 259–267 (2006).
   PubMed Web of Science ®Google Scholar
• Neal LA, Shapland W, Fox C. An open trial of moclobemide in the treatment of post-traumatic stress disorder. Into Clin. Psychopharmacol.12, 231–237 (1997).
   PubMed Web of Science ®Google Scholar
• Onder E, Tural U, Aker T. A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. Eur. Psychiatry21, 174–179 (2006).
   Google Scholar
• Becker ME, Hertzberg MA, Moore SD, Dennis MF, Bukenya DS, Beckham JC. A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J. Clin. Psychopharmacol.27, 193–197 (2007).
   PubMed Web of Science ®Google Scholar
• Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J. Clin. Psychopharmacol.26, 152–156 (2006).
   Google Scholar
• Connor KM, Davidson JRT, Weisler RH, Ahearn E. A pilot study of mirtazapine in post-traumatic stress disorder. Int. Clin. Psychopharmacol.14, 29–31 (1999).
   PubMed Web of Science ®Google Scholar
• Bahk W-M, Pae C-U, Tsoh J et al. A Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum. Psychopharmacol.17, 341–344 (2002).
   PubMed Web of Science ®Google Scholar
• Kim W, Pae C-U, Chae J-H, Jun T-Y, Bahk W-M. The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24 week continuation therapy. Psychiatry Clin. Neurosci.59, 743–747 (2005).
   Google Scholar
• Davidson JR, Weisler RH, Butterfield MI et al. Mirtazapine vs placebo in posttraumatic stress disorder: a pilot trial. Biol. Psychiatry53, 188–191 (2003).
   PubMed Web of Science ®Google Scholar
• Lewis JD. Mirtazapine for PTSD nightmares. Am. J. Psychiatry159, 1948–1949 (2002).
   Web of Science ®Google Scholar
• Chung MY, Min KH, Kim SS, Kim WC, Jun EM. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum. Psychopharmacol.19, 489–494 (2004).
   PubMed Web of Science ®Google Scholar
• Brunello N, Davidson JRT, Deahl M et al. Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology43, 150–162 (2001).
   PubMed Web of Science ®Google Scholar
• Londborg PD, Hegel MT, Goldstein S et al. Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J. Clin. Psychiatry62, 325–331 (2001).
   PubMed Web of Science ®Google Scholar
• Ciccone PE, Amzarek A, Weisbrot M, Greenstein RA, Olsem K, Zimmerman J. Pharmacotherapy for PTSD. Am. J. Psychiatry145, 1484–1485 (1988).
   Google Scholar
• Dieperink M, Erbes C, Leskela J et al. Comparison of treatment for post-traumatic stress disorder amongst three department of Veterans Affairs medical centers. Milit. Med.170, 305–308 (2005).
   PubMed Web of Science ®Google Scholar
• Hamner MB, Robert S. Emerging roles for the atypical antipsychotics in chronic post-traumatic stress disorder. Expert Rev. Neurotherapeutics5, 267–275 (2005).
   PubMedGoogle Scholar
• Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT. Evidence-based guidelines for the pharmacological management of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychpharmacol.19, 567–596 (2005).
   PubMed Web of Science ®Google Scholar
• Ursano RJ, Bell C, Eth S et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am. J. Psychiatry161(11 Suppl.), 3–31 (2004).
   PubMed Web of Science ®Google Scholar
• Foa EB, Davidson JRT, Frances A. The Expert Consensus Guideline Series: Treatment of Posttraumatic Stress Disorder. J. Clin. Psychiatry60(Suppl. 16), 3–76 (1999).
   PubMedGoogle Scholar
• Seedat S, Stein MB, Oosthuizen PP, Emsley RA, Stein DJ. Linking posttraumatic stress disorder and psychosis: a look at epidemiology, phenomenology and treatment. J. Nerv. Ment. Dis.191, 675–681 (2003).
   PubMed Web of Science ®Google Scholar
• Ahearn EP, Krohn A, Connor KM, Davidosn JRT. Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use. Ann. Clin. Pyschiatry15, 193–201 (2003).
   Google Scholar
• Kozari-Kovaci D, Pivac N, Muck-Seler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J. Clin. Psychiatry66, 922–927 (2005).
   Google Scholar
• Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS. Adjunctive risperidone in the treatment of combat-related posttraumatic stress disorder. Biol. Psychiatry57, 474–479 (2005).
   PubMed Web of Science ®Google Scholar
• Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J. Clin. Psychiatry65, 1601–1606 (2004).
   PubMed Web of Science ®Google Scholar
• Monelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J. Clin. Psychopharmacol.23, 193–196 (2003).
   Google Scholar
• Petty F, Brannan S, Casada J et al. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int. Clin. Psychopharmacol.16, 331–337 (2001).
   PubMed Web of Science ®Google Scholar
• Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology175, 451–456 (2004).
   PubMed Web of Science ®Google Scholar
• Hamner MB, Dietsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trail of adjunctive therapy. J. Clin. Psychopharmacol.23, 15–20 (2003).
   PubMed Web of Science ®Google Scholar
• Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int. J. Neuropsychopharmacol.10, 253–261 (2007).
   PubMed Web of Science ®Google Scholar
• Lipper S, Davidson JR, Grady TA, Edinger JD, Hammett EB, Mahorney SL. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics27, 849–854 (1986).
   PubMed Web of Science ®Google Scholar
• Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings: possible therapeutic effects of carbamazepine. Biol. Psychiatry23, 642–646 (1988).
   PubMed Web of Science ®Google Scholar
• Fesler FA. Valproate in combat-related posttraumatic stress disorder. J. Clin. Psychiatry52, 361–364 (1991).
   PubMed Web of Science ®Google Scholar
• Clark RD, Canive JM, Calais LA, Qualls C, Tuason VB. Divalproex in post-traumatic stress disorder: an open-label clinical trial. J. Trauma Stress12, 395–401 (1999).
   PubMed Web of Science ®Google Scholar
• Hertzberg MA, Butterfield MI, Feldman ME et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol. Psychiatry45, 1226–1229 (1999).
   PubMed Web of Science ®Google Scholar
• Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann. Clin. Psychiatry13, 141–146 (2001).
   PubMedGoogle Scholar
• Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J. Clin. Psychiatry64, 1421–1425 (2003).
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology184, 21–25 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J. Clin. Psychopharmacol.27, 85–88 (2007).
   PubMed Web of Science ®Google Scholar
• Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J. Clin. Psychiatry63(1), 15–20 (2002).
   PubMed Web of Science ®Google Scholar
• Berlant JL. Topiramate in posttraumatic stress disorder: preliminary clinical observations. J. Clin. Psychiatry62(Suppl. 17), 60–63 (2001).
   PubMed Web of Science ®Google Scholar
• Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry18(4), 24 (2004).
   Google Scholar
• Tucker P, Trautman RP, Wyatt DB et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry68(2), 201–206 (2007).
   PubMed Web of Science ®Google Scholar
• Akuchekian S, Amanat S. The Comparison of topiramate and placebo in the treatment of posttraumatic stress disorder: a randomized, double-blind study. J. Res. Med. Sci.9(5), 240–244 (2004).
   Google Scholar
• Johnson BA, Rosenthal N, Capece JA et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA298(14), 1641–1651 (2007).
   PubMed Web of Science ®Google Scholar
• Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of post-traumatic stress disorder unimproved by alprazolam treatment. J. Clin. Psychiatry51, 236–238 (1990).
   PubMed Web of Science ®Google Scholar
• Cates ME, Bishop MH, Davis LL, Lowe JS, Wooley TW. Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann. Pharmacother.38, 1395–1399 (2004).
   PubMed Web of Science ®Google Scholar
• Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J. Clin. Psychiatry57, 390–394 (1996).
   PubMed Web of Science ®Google Scholar
• Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with post-traumatic stress disorder: a review of the literature. Am. J. Psychiatry158, 1184–1190 (2001).
   PubMed Web of Science ®Google Scholar
• Kosten TR, Fontana A, Sernyak MJ, Rosenheck R. Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse. J. Nerv. Ment. Dis.188, 454–459 (2000).
   Google Scholar
• Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry65(Suppl. 1), 55–62 (2004).
   PubMed Web of Science ®Google Scholar
• Alderman CP, Gilbert AL, Condon JT. Characteristics of tranquilizer use among Australian Vietnam war veterans. Ann. Pharmacother.34, 1243–1248 (2000).
   Google Scholar
• Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction98, 1371–1378 (2003).
   PubMed Web of Science ®Google Scholar
• Bianchi M, Musch B. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int. Clin. Psychopharmacol.5, 139–145 (1990).
   PubMedGoogle Scholar
• Southwick SM, Bremmer JD, Rasmusson A, Morgan CA, Amsten A, Charney DS. Role of norepinephrine in the pathophysiology and treatment of post-traumatic stress disorder. Biol. Psychiatry46, 1192–1204 (1999).
   PubMed Web of Science ®Google Scholar
• Coupland NJ. Brain mechanisms and neurotransmitters. In: Post-Traumatic Stress Disorder – Diagnosis, Management and Treatment. Nutt DM, Davidson JR, Zohar J (Eds). Martin Duniz, London, UK, 69–100 (2000).
   Google Scholar
• Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER. The α1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with post-traumatic stress disorder: a report of four cases. J. Clin. Psychiatry61, 129–133 (2000).
   Google Scholar
• Raskind MA, Peskind ER, Kanter ED et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am. J. Psychiatry160, 371–373 (2003).
   PubMed Web of Science ®Google Scholar
• Brkanac Z, Pastor JF, Storck M. Prazosin in PTSD. J. Am. Acad. Child Adolesc. Psychiatry42, 384–385 (2003).
   Google Scholar
• Boehnlein JK, Kinzie JD. Pharmacological reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin. J. Psychiatr. Pract.13, 72–78 (2007).
   PubMedGoogle Scholar
• Peskind ER, Bonner LT, Hoff DJ, Raskind MA. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J. Geriatr. Psychiatry Neurol.16, 165–171 (2003).
   PubMed Web of Science ®Google Scholar
• Raskind MA, Thompson C, Petrie EC et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J. Clin. Psychiatry63, 565–568 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor F, Raskind MA. The α1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J. Clin. Psychopharmacol.22, 82–85 (2002).
   PubMed Web of Science ®Google Scholar
• Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. J. Nerv. Ment. Dis.177, 546–550 (1989).
   PubMed Web of Science ®Google Scholar
• Taylor F, Cahill L. Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study. J. Trauma Stress15, 433–437 (2002).
   PubMedGoogle Scholar
• Swartz CM. Betaxolol in anxiety disorders. Ann. Clin. Psychiatry10, 9–14 (1998).
   PubMedGoogle Scholar
• Pitman RK, Sanders KM, Zusman RM et al. Pilot study of sencondary prevention of posttraumatic stress disorder with propranolol. Biol. Psychiatry51, 189–192 (2002).
   PubMed Web of Science ®Google Scholar
• Vaiva G, Ducrocq F, Jezequel K et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol. Psychiatry54, 947–949 (2003).
   PubMed Web of Science ®Google Scholar
• Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent PTSD: results from a randomized controlled proof-of-concept trial in physically injured patients. J. Trauma Stress20, 923–932 (2007).
   PubMed Web of Science ®Google Scholar
• Friedman MJ. Future pharmacotherapy for post-traumatic stress disorder: prevention and treatment. Psychiatr. Clin. North Am.25, 427–441 (2002).
   PubMed Web of Science ®Google Scholar
• Schelling G, Stoll C, Kapfhammer HP et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors. Crit. Care Med.27, 2678–2683 (1999).
   PubMed Web of Science ®Google Scholar
• Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhäusler HB, Kapfhammer HP. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol. Psychiatry50, 978–985 (2001).
   PubMed Web of Science ®Google Scholar
• Schelling G, Kilger E, Roozendaal B et al. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol. Psychiatry55, 627–633 (2004).
   PubMed Web of Science ®Google Scholar
• Aerni A, Traber R, Hock C et al. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am. J. Psychiatry161, 1488–1490 (2004).
   PubMed Web of Science ®Google Scholar